Veritas Pharma’s research arm, Cannevert Therapeutics, has signed a clinical research agreement with FDI Clinical Research in San Juan, Puerto Rico, to conduct the first human study of its lead cannabis strain (CTL-X) targeting pain.   This announcement follows the previous signing of a Letter of Intent with FDI-CR to conduct a human study of CTL-X in two stages. The first stage will have an open label design to look at the feasibility of two doses of CTL-X in 5 subjects while the second...